Worried Investors are Paying up for These Stocks - Some with up to 49% Upside, Analysts Say

Dow Jones00:04

Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index

These are among the stocks in the S&P 500 consumer staples or healthcare sectors with at least 75% "buy" or equivalent ratings among analysts polled by FactSet.

So far in the fourth quarter, two of the S&P 500's defensive sectors are standing out as the best performers, and investors are paying a premium to participate.

This aligns with other signs in the stock and bond markets of investors' increasing worries about a looming recession.

Here is how the 11 sectors of the S&P 500 SPX have performed since the end of September, excluding dividends. Defensive sectors tend to outperform during economic slowdowns because their sales are based on what people need rather than what they want, which is what companies in growth sectors sell. The table also shows how the sectors' forward price/earnings ratios have changed this year.

 
Sector or index           Price change from Sept. 30 through Nov. 17  2026 price change  November price change  Forward P/E  Forward P/E at end of 2025 
Consumer staples                                               14.6%              19.3%                   2.9%         25.0                        22.3 
Healthcare                                                      9.9%              19.5%                   0.1%         19.7                        18.6 
Utilities                                                       9.8%               1.4%                  -0.3%         16.8                        17.9 
Financials                                                      6.7%               4.0%                   0.9%         14.6                        16.3 
Consumer discretionary                                          6.6%              -0.1%                   2.6%         25.7                        29.6 
Real estate                                                     6.1%               9.0%                   1.1%         17.7                        17.1 
Materials                                                       3.6%              11.4%                  -2.7%         16.9                        19.3 
Energy                                                          2.8%              41.2%                  -9.8%         12.0                        16.0 
Industrials                                                    -1.4%               6.1%                  -1.7%         21.8                        24.0 
Communication services                                        -13.9%             -10.5%                   1.6%         16.2                        22.4 
Information technology                                        -14.9%               8.9%                  -8.6%         16.7                        26.6 
S&P 500                                                        -4.1%               7.2%                  -3.2%         17.7                        22.2 
                                                                                                                                        Source: FactSet 

The S&P 500 declined 4.1% in the fourth quarter through Tuesday, and was down 3.2% for November, although it was still up 7.2% for 2026. The S&P 500's information technology sector is the worst performer in the fourth quarter and November, amid worries about the unwinding of the artificial-intelligence trade. Rapid increases in rolling weighted consensus earnings estimates have helped lower forward price-to-earnings ratios for the index and most sectors this year.

Now take a look at the two best-performing sectors so far in the fourth quarter. The consumer staples sector is up 14.6% since Sept. 30, and it is also the best November performer so far. This sector's forward P/E has increased to 25 from 22.3 at the end of last year. And the second-best performer in the fourth quarter has been healthcare, and it too has had a rising P/E, although it trades much lower on this basis than the consumer staples sector.

So these two sectors are among only three (with the real-estate sector) of 11 that have bucked the S&P 500's trend, with rising forward P/E this year.

Screening the consumer staples and healthcare sectors

Using data provided by FactSet and LSEG, we began the screen with the 33 stocks in the S&P 500 consumer staples sector and the 60 in the healthcare sector.

We narrowed the list of 93 stocks to 21 rated a "buy" or the equivalent by at least 75% of analysts polled by FactSet.

Here they are, sorted by 12-month upside potential implied by the consensus price targets:

 
Company                                           Nov. 17 price  Cons. price target  Implied 12-month upside potential  Forward P/E  2026 price change 
Bunge Global                                             $95.60             $142.10                                49%          8.8                 7% 
CVS Health                                               $85.81             $108.25                                26%          9.9                 8% 
UnitedHealth Group                                      $389.68             $475.73                                22%         16.9                18% 
IQVIA                                                   $257.60             $314.47                                22%         18.4                14% 
DexCom                                                   $82.04              $99.36                                21%         26.5                24% 
Vylor                                                    $70.21              $82.94                                18%         26.6                N/A 
West Pharmaceutical Services                            $414.12             $480.36                                16%         40.4                51% 
Danaher                                                 $225.77             $260.43                                15%         24.5                -1% 
Vertex Pharmaceuticals                                  $534.20             $601.36                                13%         27.1                18% 
Thermo Fisher Scientific                                $686.79             $766.12                                12%         25.0                19% 
Casey's General Stores                                  $713.03             $789.25                                11%         31.6                29% 
Edwards Lifesciences                                    $105.43             $115.80                                10%         31.4                24% 
AbbVie                                                  $292.82             $318.88                                 9%         18.3                28% 
Cardinal Health                                         $279.25             $302.47                                 8%         20.7                36% 
McKesson                                              $1,091.67           $1,173.21                                 7%         21.8                33% 
Labcorp Holdings                                        $368.24             $392.93                                 7%         18.8                47% 
Eli Lilly                                             $1,415.55           $1,506.42                                 6%         29.0                32% 
Mondelez International                                   $66.75              $70.42                                 5%         20.1                24% 
Walmart                                                 $127.52             $133.56                                 5%         40.4                14% 
Gilead Sciences                                         $170.26             $176.32                                 4%         19.3                39% 
Coca-Cola Co.                                            $98.79              $99.91                                 1%         28.2                41% 
                                                                                                        Source: FactSet, LSEG (for companies' sectors) 

There is no 2026 price change for Vylor $(VYLR)$, because the company was spun off by Corteva $(CTVA)$ on Oct 1. Following that transaction, S&P Dow Jones Indices announced that Vylor had taken Corteva's place in the S&P 500, with the latter moved to the S&P MidCap 400 MID.

Keep in mind that any stock screen is limited to a narrow set of data. You should do your own research to form your own opinion before buying any individual stock. One way to begin that process is to click the tickers for more about each company.

Don't miss: 14 dividend stocks selected for long-term growth

-Philip van Doorn

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment